{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:56:08Z","timestamp":1783526168017,"version":"3.55.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0239414","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T17:38:01Z","timestamp":1602005881000},"page":"e0239414","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-575X","authenticated-orcid":true,"given":"Dennie","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H. E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves J. L.","family":"Bodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Srbljin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies E.","family":"Vellekoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso M.","family":"van der Zant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto S.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko A.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-1486","authenticated-orcid":true,"given":"Max","family":"Dahele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"6","key":"pone.0239414.ref001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0239414.ref002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"RL Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0239414.ref003","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"N Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0239414.ref004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes","volume":"177","author":"MS Cookson","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"pone.0239414.ref005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"A Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0239414.ref006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"J Mohler","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"pone.0239414.ref007","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","article-title":"Cancer control with radical prostatectomy alone in 1,000 consecutive patients","volume":"167","author":"GW Hull","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"pone.0239414.ref008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0090-4295(96)00167-7","article-title":"Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer","volume":"48","author":"P Kupelian","year":"1996","journal-title":"Urology"},{"issue":"4","key":"pone.0239414.ref009","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.urology.2007.08.032","article-title":"TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications","volume":"70","author":"M Barry","year":"2007","journal-title":"Urology"},{"issue":"1","key":"pone.0239414.ref010","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"DA Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"pone.0239414.ref011","article-title":"Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer","author":"MJ Roberts","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"pone.0239414.ref012","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"P Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"pone.0239414.ref013","article-title":"Early lesion detection with (18)F-DCFPyL PET\/CT in 248 patients with biochemically recurrent prostate cancer","author":"M Wondergem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0239414.ref014","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","author":"WP Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"pone.0239414.ref015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"A Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"pone.0239414.ref016","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy","volume":"56","author":"JJ Morigi","year":"2015","journal-title":"J Nucl Med"},{"issue":"5","key":"pone.0239414.ref017","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"PJ van Leeuwen","year":"2016","journal-title":"BJU Int"},{"issue":"24","key":"pone.0239414.ref018","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Y Chen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0239414.ref019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer","volume":"17","author":"M Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"pone.0239414.ref020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges","volume":"19","author":"SP Rowe","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"pone.0239414.ref021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography","volume":"76","author":"A Sanchez-Crespo","year":"2013","journal-title":"Appl Radiat Isot"},{"key":"pone.0239414.ref022","article-title":"A Prospective Study on (18)F-DCFPyL PSMA PET\/CT Imaging in Biochemical Recurrence of Prostate Cancer","author":"E Rousseau","year":"2019","journal-title":"J Nucl Med"},{"issue":"8","key":"pone.0239414.ref023","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"A Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"pone.0239414.ref024","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","article-title":"Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy\u2014diagnostic performance and impact on therapeutic decision-making","volume":"45","author":"B Grubmuller","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0239414.ref025","volume-title":"American Joint Committee on Cancer staging manual","author":"SB Edge","year":"2010"},{"issue":"10","key":"pone.0239414.ref026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4111\/kju.2015.56.10.703","article-title":"Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy","volume":"56","author":"DS Kim","year":"2015","journal-title":"Korean J Urol"},{"issue":"10","key":"pone.0239414.ref027","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","article-title":"Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"98","author":"AJ Stephenson","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"pone.0239414.ref028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: what does it mean?","volume":"44","author":"R Tourinho-Barbosa","year":"2018","journal-title":"Int Braz J Urol"},{"issue":"2","key":"pone.0239414.ref029","first-page":"220","article-title":"Recurrence of prostate cancer after HIFU. Proposal of a novel predictive index","volume":"89","author":"U Maestroni","year":"2018","journal-title":"Acta Biomed"},{"issue":"11","key":"pone.0239414.ref030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jlcr.3430","article-title":"An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL","volume":"59","author":"HT Ravert","year":"2016","journal-title":"J Labelled Comp Radiopharm"},{"issue":"1","key":"pone.0239414.ref031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13550-016-0195-6","article-title":"Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models","volume":"6","author":"V Bouvet","year":"2016","journal-title":"EJNMMI Res"},{"issue":"3","key":"pone.0239414.ref032","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"M Eiber","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"pone.0239414.ref033","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies","volume":"73","author":"SP Rowe","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"pone.0239414.ref034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40644-016-0072-6","article-title":"(68)Ga-PSMA ligand PET\/CT in patients with prostate cancer: How we review and report","volume":"16","author":"I Rauscher","year":"2016","journal-title":"Cancer Imaging"},{"issue":"9","key":"pone.0239414.ref035","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"J Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"pone.0239414.ref036","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer","volume":"25","author":"WP Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"44","key":"pone.0239414.ref037","first-page":"741","article-title":"The diagnostic imaging of bone metastases","volume":"111","author":"W Heindel","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"3\u20134","key":"pone.0239414.ref038","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2152\/jmi.57.305","article-title":"Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer","volume":"57","author":"H Toba","year":"2010","journal-title":"J Med Invest"},{"issue":"2","key":"pone.0239414.ref039","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1148\/radiology.190.2.8284375","article-title":"Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients","volume":"190","author":"RH Oyen","year":"1994","journal-title":"Radiology"},{"issue":"1","key":"pone.0239414.ref040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41824-018-0044-0","article-title":"18F-DCFPyL PET\/CT in primary staging of prostate cancer","volume":"2","author":"M Wondergem","year":"2018","journal-title":"European Journal of Hybrid Imaging"},{"issue":"1","key":"pone.0239414.ref041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1148\/radiol.2541090361","article-title":"Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging","volume":"254","author":"CJ McMahon","year":"2010","journal-title":"Radiology"},{"issue":"2","key":"pone.0239414.ref042","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1148\/radiol.14132807","article-title":"Repeatability of metabolically active tumor volume measurements with FDG PET\/CT in advanced gastrointestinal malignancies: a multicenter study","volume":"273","author":"V Frings","year":"2014","journal-title":"Radiology"},{"key":"pone.0239414.ref043","article-title":"Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer","author":"BHE Jansen","year":"2019","journal-title":"J Nucl Med"},{"issue":"4","key":"pone.0239414.ref044","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations","volume":"31","author":"S Greenland","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"pone.0239414.ref045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"WJ Youden","year":"1950","journal-title":"Cancer"},{"issue":"2","key":"pone.0239414.ref046","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"A Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0239414.ref047","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","author":"M Perera","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"pone.0239414.ref048","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00259-019-04620-0","article-title":"(68)Ga-PSMA PET\/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is (68)Ga-PSMA PET\/CT guided biopsy the future?","volume":"47","author":"P Donato","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0239414.ref049","unstructured":"Progenics-Pharmaceuticals. Progenics Reports Results of Phase 2\/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer. 2018."},{"issue":"1","key":"pone.0239414.ref050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(17)35410-1","article-title":"The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer","volume":"150","author":"AW Partin","year":"1993","journal-title":"J Urol"},{"issue":"15","key":"pone.0239414.ref051","article-title":"A prospective phase 2\/3 multicenter study of F-18-DCFPyL PET\/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).","volume":"36","author":"MJ Morris","year":"2018","journal-title":"Journal of Clinical Oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T17:39:14Z","timestamp":1602005954000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239414"}},"subtitle":[],"editor":[{"given":"Chih-Pin","family":"Chuu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0239414","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]}}}